Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Microbot Medical ( (MBOT) ) has shared an update.
On August 20, 2025, Microbot Medical announced that it received a patent from the USPTO for a modular robotic surgical system, enhancing its LIBERTY system portfolio. This patent is expected to allow the LIBERTY device to adapt to a broader range of endovascular procedures, significantly increasing the company’s Total Addressable Market and strengthening its intellectual property protection in the U.S. The company is preparing for commercial readiness while awaiting FDA clearance, with the potential to expand its reach to over 6 million annual endovascular procedures in the U.S.
The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems.
Average Trading Volume: 1,762,202
Technical Sentiment Signal: Hold
Current Market Cap: $140.3M
For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.